Compare NVAX & AI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVAX | AI |
|---|---|---|
| Founded | 1987 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 1996 | 2020 |
| Metric | NVAX | AI |
|---|---|---|
| Price | $9.13 | $10.30 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 9 | 14 |
| Target Price | $11.33 | ★ $14.00 |
| AVG Volume (30 Days) | 4.7M | ★ 7.7M |
| Earning Date | 05-06-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 309.76 | 4.27 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,123,479,000.00 | $389,056,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 64.69 | 25.27 |
| 52 Week Low | $6.20 | $7.68 |
| 52 Week High | $11.85 | $30.11 |
| Indicator | NVAX | AI |
|---|---|---|
| Relative Strength Index (RSI) | 47.77 | 50.46 |
| Support Level | $8.89 | $9.96 |
| Resistance Level | $10.67 | $11.94 |
| Average True Range (ATR) | 0.59 | 0.75 |
| MACD | -0.08 | -0.07 |
| Stochastic Oscillator | 30.83 | 20.00 |
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Platform, which is an end-to-end application development and runtime environment for designing, developing, and deploying AI applications: C3 AI Applications, which is a portfolio of pre-built, extensible, industry-specific, and application-specific Enterprise AI applications: and C3 Generative AI, which combines the utility of large language models. Geographically the company derives revenue from North America, Europe, the Middle East and Africa, Asia Pacific, and the Rest of the World.